It seems that Albert Burla, CEO of Pfizer, knows exactly where to eat the shoulder, as he did not wait for the completion of the necessary trials so that the vaccine his company is developing in cooperation with German BioNTech can obtain the necessary approvals to start manufacturing, in order to reap the fruits from one of the largest deals expected to sell Vaccines, as the CEO of the American Pharmaceutical Company – which is the closest to the promised vaccine against the “Corona” virus – planned to sell more than $ 5.5 million of Pfizer’s shares last Monday – that is, on the same day that the company announced without essential details that a vaccine The experimental COVID-19 “has shown efficacy of more than 90%”.
This large dose of hope reflected positively on global markets, and on Pfizer’s share price in particular, which on that day reached its highest level in more than a year at $ 41.99. Burla quickly disposed of more than 132,000 shares for $ 41.94 per share, just five cents less than that peak, according to Tuesday’s stock deposit registry.
The record shows that these shares accounted for more than 60% of Burla’s holdings of Pfizer’s shares. He still owns 78,273 shares directly, in addition to 3539 others indirectly owned by him, according to what was reported by the “New York Post” newspaper.
–
–
Records reveal that Burla – who had previously earned more than $ 15 million in total direct compensation from Pfizer last year – was not the only one at the company to make such a “well-timed deal” on Monday, the vice president and director of corporate affairs at Headquarters. Manhattan, Sally Sussman, also sold more than 43,000 shares for $ 1.8 million, according to another record of filing.
Pfizer’s announcement on Monday inspired stock markets that have rebounded in the hope that a vaccine will help the global economy recover from the coronavirus pandemic. The Dow Jones Industrial Average rose 834 points to its best day since June, while Pfizer shares ended Wednesday 7.7% higher at $ 39.20.
– .
